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Abstract Using the differential display PCR method, we have 
isolated an mRNA downregulated in doxorubicin resistant 
human cell lines. The full length cDNA clone was identified as 
the human homologue of yeast RPB l l  subunit of RNA 
polymerase II. Northern blot analysis of normal tissues detected 
a particularly high expression of RPBl l  mRNA in heart and 
skeletal muscle. Reduction of this mRNA expression was 
observed in all the cell fines tested after drug treatment and 
was paralleled by a similar decrease of the protein levels. These 
findings suggest that doxorubicin may exert in vivo specific 
inhibitory effects on a major component of the transcription 
machinery. 
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I. Introduction 
The use of chemotherapeutic agents in the treatment of 
neoplastic diseases is limited by several factors including neo- 
plastic cell-specific drug resistance [1] and systemic toxicity. 
Among the chemotherapeutic agents, doxorubicin is one of 
the most effective and widely used drugs [2] and alone or in 
combination with other drugs constitutes the therapeutic 
choice for the treatment of a large array of neoplastic diseases. 
In addition to causing neoplastic ell-specific drug resistance, 
doxorubicin administration is frequently associated with car- 
diotoxic effects responsible for a high incidence of congestive 
heart failure (15-30% of patients), especially if cumulative 
drug doses exceed 500 mg/m e [3]. 
The differential display PCR is a powerful method with 
which is possible to identify altered gene expression at the 
mRNA level in any eucaryotic ell [4]. This procedure allows 
for selection of differentially expressed genes at the molecular 
level, as the fragments of cDNA obtained by PCR amplifica- 
tion are easily cloned and sequenced; moreover, the same 
fragments can be used as probes useful for Northern blot 
assays and for library screening. 
We sought to apply the differential display PCR technique 
to investigate the pattern of mRNAs expressed in human 
colon carcinoma cell lines differing for their doxorubicin sen- 
sitivity in order to identify possible markers related to drug- 
induced toxicity or resistance. 
The present study describes the isolation and cloning of an 
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mRNA differentially expressed in doxorubicin sensitive and 
resistant human cell lines. This mRNA was previously hy- 
pothesised to have a fundamental role in eucaryotic RNA 
polymerase subunits assembly similar to the one exerted in 
prokaryotic cells by the a subunit [5,6]. Our findings show 
that this message is highly expressed in human cardiac and 
skeletal muscle tissues, where the highest levels of doxorubicin 
toxicity are generally observed. Moreover, in vitro experi- 
ments on several drug-sensitive c ll lines show that the pres- 
ence of doxorubicin in the culture medium is necessary to 
downmodulate he expression of this RNA polymerase II sub- 
unit, at both the mRNA and protein levels. 
2. Materials and methods 
2.1. Cell lines and drug treatment 
LoVo (human colon carcinoma) and MCF-7 (human breast carci- 
noma) parental and doxorubicin resistant cell lines were kindly pro- 
vided by Dr. M.P. Colombo (Istituto Nazionale Tumori, Milan, Italy) 
and by Dr. K.H. Cowan (NCI, NIH, Bethesda, MD, USA). Details 
regarding the establishment and characteristics of these cell lines have 
been previously described [7,8]. The resistant cell lines were main- 
tained by continuous exposure to 0.2 mM (LoVo) or 10 mM 
(MCF-7) of doxorubicin (Adriblastina, Farmitalia Carlo Erba, Milan, 
Italy). The erythroleukemia cell line K562 was obtained from the 
American Type Culture Collection (ATCC, CCL 243) and the bladder 
carcinoma cell line EJ was kindly provided by Dr. J. Masters (Insti- 
tute of Urology, London, UK) 
2.2. Differential display PCR cDNA cloning and Northern blot analysis 
Differential display PCR was performed as previously described [4]. 
The oligonucleotides u ed for the isolation of the eDNA described in 
this paper are 5' (T)13CT, used in the first strand cDNA synthesis as 
well as in the subsequent PCR reactions, and 5' TGAGTAGGGG 
used as a random decamer in the PCR reactions. The PCR fragments 
were cloned using the TA cloning system (Invitrogen, San Diego, CA) 
according to the manufacturer's in tructions. A lambda Uni-Zap XR 
eDNA library from human colon carcinoma cell line HT29 was pur- 
chased from Stratagene (Stratagene, La Jolla, CA). DNA sequencing 
of both strands of all the cloned fragments was performed using 
specific oligonucleotides synthesised on an Applied Biosystems DNA 
synthesiser 392 model (Perkin Elmer, Roche Molecular Systems Inc., 
Branchburg, N J). 
Nucleotide and amino acid sequence analyses were performed using 
the Hitachi software Dnasis and Prosis (Hitachi Software Engineering 
America Ltd., Brisbane, CA). Data bases of reference were updated 
versions of GenBank and EMBL for DNA analysis and NBRF-PIR 
and SWIS-PROT for protein analysis. 
The cDNA sequence described is registered in GenBank with the 
accession o. L37127 and in EMBL with the accession o. X82385. 
Total cellular RNA was isolated using acid guanidinium thiocya- 
nate-phenol-chloroform extraction [9]. RNA was denatured at 65°C 
for 5 min in 50% formamide, lectrophoresed through a 1.2% agarose 
gel containing 2,2 M formaldehyde, and transferred to either nitro- 
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cellulose or nylon membranes (Amersham, Bucks, UK). Filters con- 
taining poly(A) + RNA from 16 different normal human tissues (MTN 
human blots I and II) were purchased from Clontech (Palo Alto, CA). 
Hybridizations were carried out under high stringency conditions 
using Quikhyb (Stratagene) according to the instructions of the man- 
ufacturer with randomly primed [z2P]dATP- or dCTP-labeled probes. 
Filters were exposed using X-omat AR film (Eastman Kodak Co., 
Rochester, NY) and bands were quantitated using a Phosphorimager 
with ImageQuant software (Molecular Dynamics, Sunnyvale, CA). 
2.3. Polyclonal antibody production and Western blot analysis 
The coding region of human RPB11 comprised between amino acid 
10 and 117 was cloned in the pQE-31 prokaryotic expression vector 
and the recombinant fusion protein, constructed swapping the first 10 
amino acids of huRPB11 with the 10 residues already present in the 
prokaryotic expression vector, was expressed and purified according 
to the manufacturer's protocol (Qiagen, Diagen, Hilden, Germany). 
For antiserum production, New Zealand rabbits were immunised 
4 times with 250 mg of the purified fusion protein every 2 weeks using 
Freund's adjuvants (Difco Lab., Detroit, MI) and the antiserum was 
collected 3 days after the last injection. The specific polyclonal anti- 
serum was purified using an affinity column made with recombinant 
fusion protein coupled to activated CH Sepharose according to the 
manufacturer's instruction. (Pharmacia Biotech Inc., Piscataway, NJ). 
Equal amounts of total cell lysates were immunoprecipitated with the 
purified polyclonal antibody and the samples eparated on a 12.5% 
polyacrylamide gel by SDS-PAGE under reducing conditions [10]. 
Proteins were transferred to nitrocellulose (Amersham) and blots 
were probed with the same purified polyclonal antibody. Immuno- 
reactivity was detected using an enhanced chemiluminescence kit 
(Amersham). Bands were analysed using the 2202 Ultroscan Laser 
Densitometer (LKB, Bromma, Sweden). 
additional bases at the 5'-end of the cDNAs. The longest of 
these, a 621 bp clone, was subjected to further investigation. 
3.2. Nucleotide and amino acid sequence analysis 
This latter clone contained a single open reading frame of 
351 bp coding for a protein of 117 amino acids with a calcu- 
lated Mr of 13292.62 and an isoelectric point of 5.53. A 
search in DNA and protein data banks showed a high homol- 
ogy with yeast RNA polymerase II subunit RPB l l  (Fig. 1B) 
[5]. Indeed, the two proteins shared 52% of identical and 68% 
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3. Results 
3.1. Isolation of differentially expressed mRNAs 
Using the differential display PCR method we isolated a 
cDNA clone hybridising in Northern blot analysis to an 
mRNA of about 0.6 kb. As detected with the PCR method, 
this mRNA was found to be highly expressed in both doxo- 
rubicin sensitive LoVo and MCF-7 cells, but barely detectable 
in doxorubicin resistant LoVo and MCF-7 cells (Fig. 1A). 
Northern blot analysis also detected the presence of two 
weaker bands with a higher molecular mass, suggesting that 
this gene might be either alternative spliced or a member of a 
family of closely related genes. Using the cloned fragment as a 
probe we then screened a HT29 colon carcinoma cDNA li- 
brary in order to isolate the full length clone. After three 
rounds of screening, we obtained several clones that were 
subjected to insert analysis with restriction enzymes. All of 
them showed the same pattern; therefore, three clones were 
randomly picked and sequenced. The three clones were found 
to be identical one to another with the exception of a few 
- - -)  
Fig. 1. (A) Top: Differential expression of the isolated mRNA in 
doxorubicin sensitive and resistant cell lines detected by Northern 
blotting. The blot was probed and washed under stringent condi- 
tions and exposed for 6 h at -70°C with an intensifying screen. 
Each lane contained approx. 20 ~tg of total RNA from LoVo doxo- 
rubicin sensitive (1), LoVo doxorubicin resistant (2), MCF-7 doxo- 
rubicin sensitive (3) and MCF-7 doxorubicin resistant (4) cell lines, 
respectively. The positions of 28S and 18S ribosomal RNAs are in- 
dicated. Bottom: results obtained on the same blot with a glyceral- 
dehyde phosphate dehydrogenase (GAPDH) probe. (B) Amino acid 
sequence alignment between human and yeast RPBll proteins. 
Identical residues are indicated by a colon, conserved residues by a 
period. The amino acid sequence of human RPBll was deduced 
from the HT29 derived cDNA clone. The 18 amino acid motif also 
present in other RNA polymerase subunits is underlined. 
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Fig. 2. Expression of RPBll mRNA detected by Northern blotting in 16 human normal tissues. The blot was probed and washed under strin- 
gent conditions and exposed for 3 h at -70°C with an intensifying screen. Each lane contained approx. 2 I-tg of poly(A) ÷ RNA from spleen 
(lane 1), thymus (lane 2), prostate (lane 3), testis (lane 4), ovary (lane 5), small intestine (lane 6), colon (lane 7), peripheral blood Iymphocytes 
(lane 8), heart (lane 9), brain (lane 10), placenta (lane 11), lung (lane 12), liver (lane 13), skeletal muscle (lane 14), kidney (lane 16), and pan- 
creas (lane 16). 
of conserved residues, with the major differences localised at 
the COOH-terminus. This result prompted us to identify our 
cDNA clone as the human homologue of yeast RPB11. The 
human sequence contained a previously described highly con- 
served region of 18 amino acids (underlined in Fig. 1B) that is 
also present in other RNA polymerase subunits and may be 
involved in interactions occurring among the different sub- 
units during RNA polymerase assembly [5,6]. 
3.3. Northern blot analysis on human tissues 
The expression of RPBl l  mRNA was evaluated in 16 hu- 
man normal tissues by Northern blotting. Human RPB11 was 
ubiquitously expressed in all the tissues tested, as expected for 
an mRNA coding for a subunit of the general transcriptional 
apparatus. However, in heart and skeletal muscle the expres- 
sion was 6-fold greater than in the other tissues (Fig. 2). The 
human Southem blot analysis revealed a pattern of bands 
compatible with the presence of a single copy gene as pre- 
viously described for yeast RPB11 [5] (not shown). 
3.4. Protein levels of human RPB l l  are also reduced in a doxo- 
rubicin resistant cell line 
In order to investigate whether a decrease in the relative 
protein expression paralleled the observed human RPBl l  
mRNA downregulation, cell Iysates from doxorubicin sensi- 
tive and resistant LoVo cell lines were immunoprecipitated 
using a specific rabbit polyclonal antibody (see section 2). 
The immunoprecipitated samples were separated by SDS- 
PAGE and transferred to nitrocellulose. Filters were subjected 
to Western blot analysis using the same antibody. As shown 
in Fig. 3, this antibody identified a protein with a molecular 
mass of 13 kDa in agreement with the molecular mass pre- 
dicted from the amino acid sequence and similar in size to the 
recombinant fusion protein (Fig. 3, lane 1) used to generate 
the polyclonal antibody. The huRPBll  protein, as observed 
for the huRPBl l  mRNA, was preferentially expressed in the 
doxorubicin sensitive LoVo cell line (similar results were ob- 
tained with MCF-7 cells; not shown). 
3.5. Human RPB l l  mRNA and protein downmodulation by 
doxorubicin treatment 
In order to investigate the relationship between doxorubicin 
treatment and human RPBl l  expression at the mRNA and 
protein level, we examined the effect of the drug on three 
different doxorubicin sensitive human cell lines: LoVo, EJ 
and K562. Doxorubicin administration caused a rapid and 
progressive decrease of human RPB11 mRNA in all the three 
cell lines, with the first effect being readily detectable after 24 
h and an almost complete loss of the message after 72 h (Fig. 
4A). This downmodulation was observed with a 0.2 mM Dox 
concentration i  the LoVo cell line and with a higher dose (2.0 
mM) in EJ and K562. These doses were chosen since they 
represent equitoxic drug concentrations for the different cell 
lines (not shown). 
When we tested the effects of the drug on human RPBl l  
protein expression in LoVo, EJ and K562 doxorubicin sensi- 
tive cell lines using the same drug concentrations previously 
found to affect mRNA expression, we observed a progressive 
decrease of the protein in the cell extracts (Fig. 4B). There- 
fore, these data indicate that the drug is capable of down- 
regulating human RPB 11 both at the mRNA and at the pro- 
tein level with different kinetics, possibly because of a different 
half-life of the two products. 
4. Discussion 
Using the differential display PCR technique, we have iden- 
tified and cloned an mRNA that is preferentially expressed in 
doxorubicin sensitive carcinoma cell lines. The corresponding 
cloned cDNA is the human homologue of yeast RNA poly- 
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Fig. 3. Expression of RPBll protein in doxorubicin sensitive and 
resistant LoVo cell line. The Iysates containing equal amounts of 
proteins were immunoprecipitated with the anti-human RPBll spe- 
cific polyclonal antibody. After washing, the immunocomplexes w re 
separated on SDS-PAGE and subjected to immunoblotting with the 
same antibody. Lanes: 1, recombinant fusion protein used as posi- 
tive control; 2, pre-immune serum used as negative control on 
doxorubicin sensitive LoVo colon cancer cells; 3, doxorubicin sensi- 
tive LoVo colon cancer cells; 4, doxorubicin resistant LoVo colon 
cancer cells. Ordinate, molecular weight markers run on the same 
gel. 
merase II subunit RPBll .  A screening of several human tis- 
sues by Northern blot analysis showed that this mRNA is 
highly expressed in human heart and skeletal muscle. We 
also showed that doxorubicin can rapidly modulate with dif- 
ferent kinetics human RPB11 both at the mRNA and protein 
level in different sensitive cell lines. In addition, the complete 
withdrawal of the drug from the cell culture medium of doxo- 
rubicin resistant LoVo cells induced a gradual upmodulation 
of human RPB11 mRNA levels, which, after 3 weeks, reached 
the levels observed in doxorubicin sensitive LoVo cells (not 
shown). 
Eucaryotic RNA polymerases are multisubunit enzymatic 
complexes consisting of 10-12 subunits and RPB11 is a com- 
ponent of the RNA polymerase II multisubunit complex 
[11,12]. In yeast this protein is associated with 11 other sub- 
units, is not shared among RNA polymerases I and III, and is 
also essential for cell viability [6,12,13]. The identity between 
yeast RPBl l  and the human homologue discussed in this 
paper is very high, demonstrating that this subunit is well 
conserved among eucaryotes as it has been previously shown 
for other subunits [12-14]. Interestingly, while this manuscript 
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was in progress Pati [6] described the cloning of human RNA 
polymerase II subunit hRPB14. Our sequence is identical at 
the DNA and protein level to the one described in that report 
with the exception of amino acids 14 and 16 that were erro- 
neously translated as glutamine, being instead glutamic acid, 
and with the insertion of an isoleucine at position 19. These 
corrections make the homology between the yeast and human 
gene even more stringent and underscore the fundamental role 
in transcription of these subunits. It should be noted, how- 
ever, that the major differences between yeast and human 
RPB11 subunits are encountered at the carboxy-terminal por- 
tion of the protein and that the sequence described by Pati 
differs completely from ours both at the DNA and protein 
level in the last 21 amino acids. In addition, while screening 
the cDNA library, we isolated a single clone that differed 
from the others in the carboxy-terminal portion of the protein 
but that showed no homology with the carboxy-terminal por- 
tion described by Pati (not shown). These data would suggest 
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Fig. 4, Human RPBI 1 mRNA and protein expression is affected by 
doxorubicin treatment. (A) Modulation by doxorubicin of the levels 
of human RPBll mRNA in LoVo, EJ and K562 doxorubicin sensi- 
tive cell lines. Cells were treated with 0.2 HM (LoVo) or 2.0 ktM 
(EJ, K562) doxorubicin and mRNA expression was evaluated by 
Northern blot analysis. The level of mRNAs detected in untreated 
cells is arbitrarily given as 100%. The percentage of the specific 
mRNA expression was evaluated in comparison to the [~-actin 
mRNA expression i each sample after quantitation as specified in 
section 2. (B) Modulation by doxorubicin of the level of human 
RPBll protein in doxorubicin sensitive LoVo, EJ and K562 cell 
lines. Cells were treated with either 0.2 ~tM (LoVo) or 2.0 ~tM (EJ, 
K562) doxorubicin. The level of the protein detected in untreated 
cells was assumed as 100%. Quantitation of the protein expression 
was performed as described in section 2. 
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that possible alternative splicings may occur in this part of the 
protein generating multiple transcripts. Moreover, since the 
clone described by Pati was isolated from a different cellular 
source than the one used in this paper, it is possible that 
different tissues may utilise peculiar carboxy-terminal se- 
quences, the significance of which has yet to be determined. 
To clarify this point we are in the process of characterising the 
genomic structure of the gene. 
Doxorubicin has been described to have specific and sys- 
temic toxic effects through several mechanisms of action. Rec- 
ognised among them have been the generation of oxygen free 
radicals [15], the interaction with cell membrane constituents 
[16] and the induction of large gene deletions in mammalian 
cells [17] probably through the stabilisation of the intermedi- 
ate ternary complex DNA-topoisomerase II [18]. 
Selective action on several genes has also been reported. In 
particular, a downmodulation of the mRNA levels for the 
sarcomeric genes ~-actin, troponin I, myosin light chain 2, 
the muscle specific M isoform of creatine kinase [19], MyoD 
and myogenin [20] has been associated with the specific car- 
diotoxic effects of doxorubicin. In addition, other genes have 
been found to be overexpressed and the presence of doxoru- 
bicin response lements in the 5'-region of the human Id2 
gene has been hypothesised [21], strongly suggesting that 
doxorubicin may exert specific functions on the transcription 
machinery. Interestingly, it has also been reported that a 
crude preparation of RNA polymerase II was inhibited in 
its transcriptional ctivity by doxorubicin and this effect was 
attributed to a reduction of RNA chain initiation [22]. The 
data presented in this report further support he latter find- 
ings, characterising an essential component of the general 
transcriptional pparatus [5,6] as a target hrough which dox- 
orubicin may exert both specific and systemic toxicity. Ac- 
cordingly, we believe that doxorubicin administration in 
vivo would result in specific negative ffects on the transcrip- 
tional activity (this paper and [22]) of those tissues, like the 
heart, expressing the highest levels of the protein and under- 
going a rapid metabolic turnover. In contrast, in doxorubicin 
resistant cells the selection process may have induced modifi- 
cations in the half-lives of either human RPBl l  mRNA or 
protein resulting in a proliferative advantage for these cells. 
Further experimental data are needed to corroborate this 
pathogenetic hypothesis. In addition, we cannot exclude that 
doxorubicin may also exert these inhibitory effects on other 
components of the RNA polymerase II enzymatic omplex. 
Finally, the cloning and availability of a new subunit of 
RNA polymerase II provide additional tools to understand 
the structure and role of this molecule and its subunits in 
the process of gene transcription and its regulation. 
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